Westborough, MA (Vocus) October 12, 2010
When: October 13, 2010 3:00 PM - 3:45 PM
2010 World Health Forum – Boston
Harvard Medical School, Joseph B. Martin Conference Center, Elements
Ten years ago the human genome was sequenced for the first time. In the intervening years, advances in research and new technologies have yielded great promise for personalized medicine in the clinic, but often times results have fallen short of expectations. Still, the latest PriceWaterHouseCoopers report on personalized medicine estimates that the market will grow to nearly $500 billion in 2015, and terms it a “disruptive innovation” for life sciences. The firm predicts that collaboration on innovation will become a “core skill” and forecasts collaborative efforts with supporting IT across pharmaceutical firms, biotech, health care providers and payers, and government.
Building on “A Call to Action” for the medical profession to catch up with the technology and business communities in the application of genomics to personalized medicine, the Department of Pathology at Beth Israel Deaconess Medical Center today announces a collaboration with GenomeQuest to create a new clinical model that applies genomics technologies in the diagnosis of disease, expanding beyond the traditional diagnostic tools used by pathologists.
- Harry Glorikian, Founder and Managing Partner, Scientia Advisors
- Mark Boguski, MD, PhD, Beth Israel Deaconess Medical Center Department of Pathology and Center for Biomedical Informatics, Harvard Medical School
- Richard Resnick, CEO of GenomeQuest
Jerry Berger, (617) 667-7308; jberger(at)bidmc(dot)harvard(dot)edu
Dana Wormer, (215) 888.0960; dana(dot)wormer(at)redzebraworks(dot)com
# # #